Tag Archives: Hemostemix

Calgary, Alberta–(Newsfile Corp. – December 4, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. …

Calgary, Alberta–(Newsfile Corp. – December 3, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, …

Calgary, Alberta–(Newsfile Corp. – December 2, 2025) – Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas – the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. …

Calgary, Alberta–(Newsfile Corp. – July 31, 2025) – Further to its press release dated July 24, 2025, Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) wishes to provide an update regarding its previously closed non-brokered private placement (the “Offering“). The Company confirms that, following the receipt …

Calgary, Alberta–(Newsfile Corp. – July 31, 2025) – Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient’s own ACP-01 and …

Calgary, Alberta–(Newsfile Corp. – July 17, 2025) – Further to the June 26 and July 9th press releases announcing the Hemostemix Inc’s (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) non-brokered private placement of $2,500,000 and its oversubscription, the Company has accepted additional over-subscriptions totalling $500,000. The Company …

Calgary, Alberta–(Newsfile Corp. – July 4, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) announces that the TSX Venture Exchange (“TSXV“) conditionally approved the Company’s previously disclosed non-brokered private placement (the “Offering“) in the amount of CAD $469,366. The Offering consisted of the issuance …

Calgary, Alberta–(Newsfile Corp. – July 3, 2025) –  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous Angiogenic Cell Precursors-A Molecular Strategy for The Treatment of Heart Failure: Response to BioCardia‘s Cardiamp HF Trial. Recent research has revealed …

Calgary, Alberta–(Newsfile Corp. – June 27, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen …

Freiburg, Germany–(Newsfile Corp. – May 20, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for cardiovascular diseases, is presenting its groundbreaking clinical trial results and regenerative medicine innovations today at the Tissue Engineering and Regenerative Medicine International Society …